Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Glutathione and Roxadustat — mechanism, side effects, legal status, and pricing.
Glutathione is an endogenous tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine) that serves as the principal intracellular antioxidant in mammalian cells. It is not FDA-approved as a drug in the US; parenteral glutathione is used off-label (and in some compounding settings) for oxidative stress, hepatic support, and — controversially — skin lightening. The FDA has warned against injectable glutathione for skin lightening (2019) due to reports of serious adverse events.
Roxadustat (Evrenzo) is a small-molecule HIF-prolyl-hydroxylase inhibitor — not a peptide — that raises endogenous erythropoietin. It is an approved prescription drug for anemia of chronic kidney disease in China, Japan, and the EU, but the US FDA rejected it over safety signals. Because it boosts EPO/hemoglobin, it is diverted to the gray market for endurance doping and is WADA-prohibited at all times.
Glutathione
Roxadustat
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Glutathione
Roxadustat
No pricing data yet.
Check Roxadustat prices →COA corpus from Disclosed Labs — independently tested batches only.
Glutathione
62
COAs
99.5%
Avg purity
10
Labs
Roxadustat
3
COAs
99.8%
Avg purity
2
Labs
A randomized, double-blind pilot trial (Hauser et al., Movement Disorders, 2009, PMID 19230029) tested IV glutathione 1,400 mg three times weekly for 4 weeks in Parkinson's disease (n=21); it was well tolerated but did NOT show a statistically significant effect on UPDRS scores. A large randomized trial of inhaled glutathione (646 mg every 12 hours for 6 months) in cystic fibrosis (Griese et al., Am J Respir Crit Care Med, 2013, PMID 23631796) did not demonstrate clinically relevant improvements in lung function, exacerbations, or quality of life. Oral glutathione has poor bioavailability due to GI degradation, driving investigation of IV, nebulized, liposomal, and sublingual delivery. The FDA issued a 2019 warning about compounded sterile injectable glutathione made from dietary-grade ingredient, citing adverse-event reports (including Stevens-Johnson syndrome, toxic epidermal necrolysis, and kidney dysfunction) particularly in the context of unregulated IV skin-lightening use.
Key references
Roxadustat is supported by extensive human data as an approved anemia drug (China 2018, Japan 2019–2020, EU 2021 as Evrenzo) with numerous Phase 2/3 CKD trials. The US FDA advisory committee voted against approval in July 2021, citing thrombosis, seizures, infections, and mortality signals. No validated recreational or performance dose exists. Not FDA-approved; not a peptide.
Glutathione (Immune) and Roxadustat (Metabolic) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs